BioAge Labs, Inc. (BIOA)
BIOA moved a median of -0.34% 30 minutes after news, and -0.19% by the close. How BIOA actually reacts to news — the realized, point-in-time move the market made, measured across 1,521 labeled events over the last three years with zero look-ahead.
BIOA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 40% | 1,402 |
| 30-min | -0.34% | 38% | 1,454 |
| 60-min | -0.40% | 39% | 1,454 |
| to close | -0.19% | 48% | 1,456 |
| Middle 50% of BIOA reactions | -1.94% to +0.69% |
|---|---|
| Median reaction (30-min) | -0.34% |
| Measured reactions | 1,521 |
Half of all BioAge Labs, Inc. news events land between -1.94% and +0.69% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How BIOA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 15 | +1.01% | 60% | +0.94% |
| Analyst downgrades | 11 | -1.72% | 27% | -4.28% |
| Coverage initiations | 25 | -0.93% | 48% | +1.01% |
| Rating reiterations | 18 | +0.19% | 56% | +0.26% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how BIOA ranks against every other measured name →
That’s how BIOA usually reacts — get an email when it moves on news →Email me when BIOA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BIOA's baseline. Nothing else.
Recent BIOA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target | Press release | GlobeNewswire | +0.36% | -1.27% | |
| Form 8-K BioAge Labs, Inc. For: Oct 02 | SEC filing · Form 8-K | SEC EDGAR | -3.31% | -4.36% | |
| BioAge Labs to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +0.00% | +0.98% | |
| First patient treated with Leqembi® (lecanemab) in Sweden | Press release | PR Newswire | +0.00% | +3.30% | |
| Leqembi® Pen subcutaneous formulation approved in Japan | Press release | PR Newswire | -0.67% | -5.60% | |
| BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema | Press release | GlobeNewswire | -0.74% | -1.10% | |
| BioAge Labs to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +2.19% | +1.46% | |
| Number of shares and votes in BioArctic AB (publ) as of August 31, 2026 | Press release | PR Newswire | -0.54% | +2.04% | |
| Leqembi Iqlik® for initiation treatment launched in the US | Press release | PR Newswire | -1.08% | -1.99% | |
| BioArctic and Mesenkia enter oncology research collaboration | Press release | PR Newswire | -1.87% | +0.56% | |
| Invitation to presentation of BioArctic's second quarter report for April - June 2026 on August 26 at 9:30 a.m. CEST | Press release | PR Newswire | -1.87% | +0.56% | |
| BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | -0.05% | +3.30% | |
| Form 10-Q BioAge Labs, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.05% | +3.30% | |
| Form 8-K BioAge Labs, Inc. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -0.05% | +3.30% | |
| HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction | Press release | PR Newswire | -0.36% | +3.31% | |
| More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026 | Press release | PR Newswire | +0.36% | +3.64% | |
| FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease | Press release | PR Newswire | -0.36% | +3.31% | |
| New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease | Press release | PR Newswire | -2.08% | -8.54% | |
| New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026 | Press release | PR Newswire | -1.44% | -1.92% | |
| BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology | Press release | PR Newswire | +2.03% | +2.92% | |
| BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk | Press release | GlobeNewswire | -1.26% | +3.28% | |
| Form 8-K BioAge Labs, Inc. For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +0.24% | +9.53% | |
| Number of shares and votes in BioArctic AB (publ) as of May 29, 2026 | Press release | PR Newswire | -0.03% | +0.82% | |
| Bulletin from the Annual General Meeting in BioArctic AB (publ) | Press release | PR Newswire | -0.36% | +1.07% | |
| BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day | Press release | PR Newswire | -0.18% | -3.11% | |
| BioAge Labs to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +1.66% | -1.48% | |
| Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027) | Press release | PR Newswire | -0.25% | -2.81% | |
| A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Avaí Bio's Cell-Based Platform Approach | Press release | PR Newswire | -0.14% | -2.22% | |
| Invitation to presentation of BioArctic's first quarter report for January - March 2026 on May 20 at 9:30 a.m. CET | Press release | PR Newswire | -0.54% | +3.18% | |
| BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | -0.23% | +2.68% | |
| Form 10-Q BioAge Labs, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.23% | +2.68% | |
| Form 8-K BioAge Labs, Inc. For: May 08 | SEC filing · Form 8-K | SEC EDGAR | -0.23% | +2.68% | |
| Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S. | Press release | PR Newswire | -0.23% | +2.68% | |
| BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 | Press release | GlobeNewswire | +0.56% | -0.77% | |
| BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP | Press release | GlobeNewswire | -0.32% | +4.31% | |
| BioArctic publishes the Annual Report and Sustainability Report for 2025 | Press release | PR Newswire | +0.66% | -0.63% | |
| Form ARS BioAge Labs, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.55% | -7.55% | |
| Form DEF 14A BioAge Labs, Inc. For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | +0.55% | -7.55% | |
| Form DEFA14A BioAge Labs, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.55% | -7.55% | |
| BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference | Press release | GlobeNewswire | +1.16% | +1.47% | |
| The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB | Press release | PR Newswire | -0.53% | -4.44% | |
| BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 | Press release | GlobeNewswire | -0.49% | -12.87% | |
| Form 10-K BioAge Labs, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.49% | -12.87% | |
| Form 8-K BioAge Labs, Inc. For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | -0.49% | -12.87% | |
| Form S-3ASR BioAge Labs, Inc. | SEC filing · Form S-3ASR | SEC EDGAR | -3.16% | +0.80% | |
| Form S-8 BioAge Labs, Inc. | SEC filing · Form S-8 | SEC EDGAR | -3.16% | +0.80% | |
| New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress | Press release | PR Newswire | +0.29% | -3.02% | |
| BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | -0.69% | +1.89% | |
| Invitation to presentation of BioArctic's fourth quarter report for October - December 2025 on February 18 at 9.30 a.m. CET | Press release | PR Newswire | -0.62% | -0.99% | |
| Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025 | Press release | PR Newswire | +4.40% | +2.52% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BIOA section they belong to.
Where else BIOA is measured.
BIOA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is BioAge Labs, Inc.'s median reaction calculated?
Every labeled BIOA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1,521 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 38% of BIOA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BIOA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.